BREAKTHROUGH PRIZE ANNOUNCES 2024 LAUREATES IN LIFE SCIENCES, FUNDAMENTAL PHYSICS, AND MATHEMATICS
Life Sciences Carl June and Michel Sadelain were awarded the 2024 BREAKTHROUGH PRIZE in Life Sciences for genetically engineered T cells – key ...
read moreMonday, August 7, 9:10 AM Dr. Bamdad will present: Phase I/II Trial of MUC1*-Targeting CAR T Cells for Solid Tumor Cancers
Previous attempts to therapeutically target MUC1 failed because they targeted the tandem repeat domain, which is shed from tumor cells. Cancer cells express a cleavage ...
read moreDr. Cynthia Bamdad will present next generation cancer immunotherapy at annual meeting of AACR April 16th
News ReleasesDr. Bamdad will show latest data in presentation “1XX mutations slow CAR T cell signaling and increase in vivo persistence”, Sunday 16 th 3:10 ...
read moreFDA approved IND huMNC2-CAR22 for Clinical trials
News ReleasesJanuary 09, 2023 --FDA has approved their IND (Investigational New Drug) application to conduct clinical trials with huMNC2-CAR22, aka MUC1*-CAR-1XX, for the treatment of ...
read moreASGCT 25th Annual Meeting May 19 11:00am ET Room 207: “CAR T That Targets MUC1 Transmembrane Cleavage Product Has Increased Persistence and Kills Low Antigen Cells,”
EventsDr. Cynthia Bamdad will present some of Minerva’s latest scientific findings at the 25th Annual Meeting of ASGCT (American Society of Cell and Gene Therapy), on Thursday ...
read moreISCT 2022 San Francisco, 1st -IN-HUMAN CAR T HITS MUC1* GROWTH FACTOR RECEPTOR
Poster 501 Thursday May 5, 17:45 - 19:15 ⇒ 5:45 - 7:15 PST Elevator Pitch 18:00 - 19:00 ⇒ 6:00 - 7:00 PST
read morePEGS Boston May 2-6 Dr. Cynthia Bamdad, First-in-Human Trial of CAR T Targets MUC1 transmembrane Cleavage Product: Wednesday May 4th 4:30 – 5:00 Ballroom C
Trial at the City of Hope, Duarte CA .. NCT04020575
read moreAACR 2022 Annual Meeting in New Orleans April 12, 2022 1:30 PM - 5:00 PM
News Releases“ Novel anti-NME7antibody inhibits metastasis of solid tumor cancers ” Minerva’s CEO, Dr. Cynthia Bamdad, will present a poster describing the ...
read moreMinerva Biotechnologies announces opening 1st-in-human Phase I/II trial of a MUC1* targeting CAR T for metastatic breast cancers at City of Hope
News ReleasesWALTHAM, MA – Minerva Biotechnologies Corporation announced today that its trial of huMNC2-CAR44 T cells (NCT04020575) has now opened at City of Hope, Duarte, ...
read moreMinerva Biotechnologies Announces License Agreement with Memorial Sloan Kettering Cancer Center for 1XX Technology
News ReleasesWALTHAM, MA June 22, 2020 – Minerva Biotechnologies (Minerva) today announced that it has licensed from Memorial Sloan Kettering Cancer Center (MSK) ...
read moreMinerva's First-In-Human Clinical Trial Featured in Article on Cancer Therapy Advisor
News ReleasesMinerva's First-in-Human clinical trial is featured in an article by Julia Sklar in Cancer Therapy Advisor. The article goes into depth about how Minerva's ...
read moreMinerva Biotechnologies Announces FDA Acceptance of IND Application for huMNC2-CAR44 T cells to Treat Metastatic Breast Cancer
News ReleasesWALTHAM, MA - Minerva Biotechnologies, a biopharmaceutical company focused on developing immunotherapies for cancer and cellular therapies in regenerative medicine, announced ...
read more
